<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04171349</url>
  </required_header>
  <id_info>
    <org_study_id>Articaine</org_study_id>
    <nct_id>NCT04171349</nct_id>
  </id_info>
  <brief_title>Articaine vs Dexmedetomidine Supplemented Articaine</brief_title>
  <official_title>Articaine and Dexmedetomidine - Supplemented Articaine for Arteriovenous Fistula Creation Under Ultrasound- Guided Supraclavicular Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study to test efficacy of adding dexmedetomidine to articaine on sensory,
      motor and duration of analgesia during hemodialysis fistula creation under ultrasound guided
      supraclavicular block
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult fifty patient with chronic renal failure on hemodialysis, scheduled for arteriovenous
      fistula creation under ultrasound guided supraclavicular block. Patients were randomly
      allocated in two group. The articaine group (group A) received 40 ml articaine hydrochloride
      2% and articaine-dexmedetomidine group (group AD) received 40 ml. Of articaine 2% mixed with
      dexmedetomidine (1micogram/kg)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Actual">November 1, 2019</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of sensory block</measure>
    <time_frame>24 hours</time_frame>
    <description>Sensory block time tested by pinprick test measured in minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of motor block</measure>
    <time_frame>24 hours</time_frame>
    <description>Motor block time tested by Bromage scale measured in minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of analgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>Measured by visual analog scale score 4</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sedation</measure>
    <time_frame>24 hours</time_frame>
    <description>Measured by Ramsay sedation scale score 3</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received ultrasound guided supraclavicular block with 40 ml of Articaine hydrochloride 2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group AD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received ultrasound guided supraclavicular block with 40 ml articaine 2% mixed with dexmedetomidine (1 Âµg/kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Articaine</intervention_name>
    <description>Vial</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group AD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Vial</description>
    <arm_group_label>Group AD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patient with chronic renal failure on hemodialysis scheduled for radiocephalic
             fistula creation

        Exclusion Criteria:

          -  Allergy to local anesthetics.

          -  Infection at the site of needle insertion.

          -  Those having international normalized ratio more than 1.5.

          -  Coagulopathy.

          -  Neuromuscular, or severe hepatic or severe pulmonary disease.

          -  Those having epilepsy.

          -  Patients who refused to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Galal Mo Professor, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams University hosptal</name>
      <address>
        <city>Cairo</city>
        <state>Abbasya</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 15, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>simon Halim Armanious</investigator_full_name>
    <investigator_title>Simon Halim, MD S. Armanious</investigator_title>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Carticaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participants data for all primary and secondary outcome measures will be available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Within 6 month after study completion</ipd_time_frame>
    <ipd_access_criteria>Data access request will be reviewed by external independent reviewers panal. Request will be required to sign data access</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

